A phage display nanobody discovery service uses a VHH antibody library to identify candidate nanobodies that bind a buyer’s target. A typical project may include target and assay planning, library selection (panning), clone screening, sequence analysis, and delivery of agreed candidates and data. Before requesting a quote, define the target format, intended application, validation criteria, and exactly which materials and records you expect. For veterinary medicine projects, also clarify whether candidates are for research or diagnostic development; discovery-stage binding results alone do not establish diagnostic performance, safety, or suitability for use in animals.
This guide is for biotechnology companies, veterinary diagnostic developers, animal-health organizations, and research teams considering outsourced nanobody discovery. It is particularly relevant when the target is a veterinary pathogen, toxin, disease-associated protein, or other molecule linked to animal health. It can also help procurement and project managers compare proposals that use different workflows or define “validated hit” differently.
The right service scope depends on what you need to do with the binder. A candidate for a research assay may have different validation needs from one intended for a lateral-flow test, immunoassay, imaging reagent, or later therapeutic research. State the intended use early so the provider can discuss relevant formats and limitations without implying that discovery alone qualifies a candidate for clinical or field use.
Phage display links a displayed antibody fragment to the genetic information encoding it, allowing target-binding clones to be enriched and recovered. In nanobody discovery, the displayed binder is generally based on a single-domain antibody format such as a VHH. VHH domains are commonly described as approximately 110–130 amino acids, although the exact length depends on sequence and construct boundaries.
The service usually begins with a feasibility and design discussion. The provider reviews target identity, purity, species or strain relevance, available target formats, and the intended assay. Selection and screening conditions are then chosen to reduce the risk that apparent binding reflects a tag, carrier, plate surface, or other assay component rather than the target of interest.
Provide the target’s name, sequence or accession where available, species, construct boundaries, and known variants. For veterinary applications, identify the animal species and pathogen strains or target variants that matter to the program. Explain whether you need binding to purified antigen, native target on cells, or performance in a defined assay matrix.
Ask the provider to review target format, sample quantity, storage and shipping requirements, and any known stability concerns. Agree on negative controls and, where relevant, counter-selection against homologous proteins, tags, or non-target cells. If the target is scarce or difficult to produce, establish how failed or inconclusive selection will be handled before authorizing work.
The provider performs selection cycles intended to enrich target-binding phage, then tests individual clones using an agreed screening method. The number of cycles and clones screened is project-specific. For proposal comparison, ask the provider to quote an exact scope—for example, 3 selection rounds and screening of 96 clones—rather than assuming those figures are standard or sufficient for every target.
Positive screening signals should be followed by sequence identification and, where included, further testing using expressed soluble nanobody. Ask whether validation checks binding specificity, concentration-dependent response, target format, or binding in your intended assay. A phage-screening signal is an initial result, not by itself proof of affinity, specificity, functional activity, or diagnostic utility.
If you want to learn more, please visit our website NBbiolab.
At project close, confirm whether you will receive sequences, clone IDs, plasmids or phage, expressed protein, and experimental records. Clarify sample format, quantity, concentration, buffer, and shipping conditions where physical material is included. Also establish the permitted use of sequences and materials, ownership terms, confidentiality, and any restrictions on downstream use.
A useful deliverable package should make it possible to interpret and reproduce the discovery-stage findings. At minimum, ask whether the report will identify each candidate, describe the screening and validation methods, and present the criteria used to call a hit. Request assay controls and relevant raw or processed data when available under the agreed scope.
| Deliverable | What to confirm |
|---|---|
| Sequence information | Full coding or amino-acid sequences, clone identifiers, and construct details. |
| Screening results | Assay method, controls, hit criteria, and data for positive and negative comparisons. |
| Candidate material | Whether phage, plasmid, or soluble protein is included, with quantity and format specified. |
| Project report | Workflow summary, candidate ranking rationale if provided, limitations, and recommended next steps. |
There is no single price or turnaround that applies to every discovery project. Cost and schedule can depend on library type, target complexity, assay development, material availability, number of candidates to test, and whether expression or additional validation is included. A quoted timeline should specify its starting point and assumptions, such as receipt and acceptance of the target material.
Request a scope-based quote that separates core discovery from optional services. As an example of useful quote units, ask for the number of selection rounds, the number of clones screened, and the estimated project duration in weeks; a provider might be asked to price a plan based on 3 rounds, 96 clones, and an 8–16-week planning window. These are comparison examples only, not recommended defaults or a promise that a project will fit that schedule. Confirm any minimum sample requirements and how additional screening or repeat work is priced.
A common mistake is sending only a target name without its format, intended use, or relevant variants. This can lead to a selection strategy that detects binding to a recombinant construct but does not answer the buyer’s real assay question. Provide target documentation and discuss controls before agreeing to the experimental plan.
Another risk is treating “number of hits” as the only measure of success. Multiple weak or redundant candidates may be less useful than a smaller, well-documented set with distinct sequences and relevant validation. Agree on what counts as a deliverable hit, whether sequence diversity matters, and which follow-up experiments are included versus separately quoted.
A phage display nanobody discovery service can take a project from target planning through selection, screening, sequence identification, and agreed validation. The buyer’s most important task is to align the workflow with the target and intended veterinary application, then document the expected materials, data, and decision criteria. Discovery results should be treated as candidates for further evaluation, not as automatic evidence of diagnostic or therapeutic readiness.
Before selecting a supplier, share your target details and application, request a written workflow and deliverables list, and compare the assumptions behind each quote. NBbiolab can discuss project scope, target presentation, screening options, and reporting expectations for a custom nanobody discovery program. Contact our team with your target information and intended use to request a project assessment and quotation.
If you are looking for more details, kindly visit Phage Display Nanobody Discovery Service.